NCT01224067View on ClinicalTrials.gov

Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

October 31, 2008

Conditions
Social Anxiety Disorder
Interventions
DRUG

Quetiapine

Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.

Trial Locations (1)

02139

Cambridge Health Alliance, Cambridge

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Cambridge Health Alliance

OTHER